June 27, 2018 01:47 PM EDTUpdated June 28, 06:15 AM
Pharma

Ar­ray wres­tles FDA OK for its MEK/BRAF melanoma com­bo, to hit the phar­ma­cy as Mek­tovi and Braftovi

John Carroll

Editor & Founder

Watch out No­var­tis.

Just a few weeks af­ter turn­ing up at AS­CO with pos­i­tive da­ta to show off, Ar­ray Bio­Phar­ma $AR­RY has nailed an FDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

J&J, Leg­end’s Carvyk­ti clears a type of blood can­cer in ‘nine out of 10’ pa­tients

'It's the bi­ol­o­gy, stu­pid': Re­la­tion and GSK team up on fi­bro­sis, os­teoarthri­tis

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times